SEC Form 4 · accession 0001181431-15-002030
Orexigen Therapeutics, Inc. · OREXQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Narachi
Officer — President and CEO · Director
Period of report
Feb 3, 2015
Accepted (ET)
Feb 5, 2015 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $5.34 | Feb 3, 2015 | A | 635,150 | A | — | Feb 2, 2025 | Common Stock | 635,150 | 635,150 | D |
Explanation of responses
- F11/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2015, so that all of the shares of the stock subject to the option shall be vested on 2/3/2019, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date.
- F2Not applicable.